Adefovir: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
'''Adefovir dipivoxil''', previously called '''bis-POM PMEA''', with trade names '''Preveon®''' and '''Hepsera®''', is an orally-administered nucleotide analog [[reverse transcriptase inhibitor]] (ntRTI) used for treatment of [[hepatitis B]]. It is a failed treatment for [[HIV]]. | |||
==Category== | ==Category== | ||
Revision as of 00:48, 2 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Adefovir dipivoxil, previously called bis-POM PMEA, with trade names Preveon® and Hepsera®, is an orally-administered nucleotide analog reverse transcriptase inhibitor (ntRTI) used for treatment of hepatitis B. It is a failed treatment for HIV.
Category
Antiviral
US Brand Names
HEPSERA®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | Compatibility, Reconstitution, and Stability | Directions For Use | How Supplied | Labels and Packages